Anticoagulants, Antiplatelets, and Thrombolytics

Slides:



Advertisements
Similar presentations
Chapter 19 Hematologic Products.
Advertisements

Drugs for Coagulation Disorders
Drugs for Coagulation Disorders Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 8, 2008
Chapter 19 Agents Affecting Blood Clotting. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Blood.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Vascular Pharmacology
PTP 546 Module 6 Cardiovascular Pharmacology: Part II Jayne Hansche Lobert, MS, RN, ACNS-BC, NP 1Lobert.
Coagulation Modifier Drugs
Anticoagulation in the Acute Care Population Aimee Ring PT, DPT, GCS.
Antiplatelet Drugs (Anti-thrombotics)
C OAGULATION M ODIFIER D RUGS Lilley Reading and Workbook, Chap 27.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 28 Coagulation Modifier Drugs.
Agents Affecting Blood Clotting. Anticoagulant Agents Prevent the extension and formation of clots. Inhibition by interference with the ‘coagulation cascade’
Anticoagulant, Fibrinolytic and Antiplatelet
ANTICOAGULANT BY :DR ISRAA OMAR.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs 4 October :06 PM.
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Thrombolytic drugs BY :DR. ISRAA OMAR.
ANTIPLATELET DRUGS.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 27 Coagulation Modifier Drugs.
Anticoagulations and Coagulants
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar.
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar
Anticoagulants, Thrombolytic Agents and Antiplatelet Drugs
Agents Affecting Blood Clotting
Dr. Laila M. Matalqah Ph.D. Pharmacology
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Chapter 19 Agents affecting Blood Clotting. Blood Clotting p461 Clotting is necessary to prevent fatal loss of blood from a minor injury Thromboemboli.
DVT cases.  Heparin, low molecular weight heparin, or fondaparinux are usually continued for at least five days, along with another medication called.
Prof. Abdulrahman Almotrefi
Anticoagulants, Antiplatelets, and Thrombolytics
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Drugs Used in Coagulation Disorders Presented by Dr. Sasan Zaeri PharmD, PhD.
Drugs Used in Coagulation Disorders
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
II. Antiplatelet Drugs.
Chapter 23 Thrombo-Embolic diseases
23 Anticoagulants.
Drugs affecting coagulation and dental management
Blood/Blood Formation
Regional anesthesia on anticoagulants
Anticoagulants and Antiplatelets
Management of ST-Elevation Myocardial Infarction
Fibrinolytic Drugs (Thrombolytic Drugs )
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
The normal haemostasis process involves three stages: 1
Coagulation Modifier Drugs
Coagulation Modifier Drugs
Coagulation Disorders
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Chapter 17 Hematologic Products
23 Anticoagulants.
Drugs Affecting Blood.
Anticoagulants.
Prof. Abdulrahman Almotrefi
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Presentation transcript:

Anticoagulants, Antiplatelets, and Thrombolytics Chapter 45 Anticoagulants, Antiplatelets, and Thrombolytics Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Drugs Used to Maintain or Restore Circulation Anticoagulants: Prevent the formation of clots that inhibit circulation Antiplatelets (antithrombotics): Prevent platelet aggregation Thrombolytics: Attack and dissolve blood clots that have already formed Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Thrombus Formation Pathophysiology Formation of clot in artery or vein Caused by decreased circulation, platelet aggregation on vessel wall, blood coagulation Arterial clot formation Platelets initiate process. Fibrin formation occurs. RBCs are trapped in fibrin mesh. Venous clot formation Platelet aggregation with fibrin that attaches to RBCs Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Action of the Parenteral Anticoagulant Heparin Anticoagulants Heparins Action of the Parenteral Anticoagulant Heparin Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Anticoagulants (Cont.) Heparins Low-molecular-weight heparin (LMWH): enoxaparin sodium (Lovenox), dalteparin sodium (Fragmin), and tinzaparin sodium (Innohep) Contraindications Stroke, peptic ulcer, blood anomalies Patients having eye, brain, or spinal surgery Administration of heparins Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Anticoagulants (Cont.) Heparins Most commonly prescribed to prevent DVT and acute pulmonary embolism after orthopedic or abdominal surgery Heparin laboratory values PTT 1.5 to 2 times control value (control 60 to 70 seconds) aPTT 30 to 85 seconds (control 20 to 35 seconds) Side effects Bleeding Protamine Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Direct Thrombin Inhibitors Directly inhibit thrombin from converting fibrinogen to fibrin Administered intravenously: Argatroban (Acova) Bivalirubin (Angiomax) Lepirudin (Refludan) Administered subcutaneously: Desirudin (Iprivask) Oral anticoagulant that does not require routine coagulation monitoring: Dabigatran (Pradaxa) Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Warfarin (Coumadin) Oral anticoagulants Inhibit hepatic synthesis of vitamin K, thus affecting the clotting factors II, VII, IX, and X Used mainly to prevent thromboembolic conditions such as thrombophlebitis, pulmonary embolism, and embolism formation caused by atrial fibrillation, which can lead to a stroke (CVA) Monitor therapeutic range PT 1.25 to 2.5 times control value (11 to 15 seconds) INR 2 to 3 (normal 1.3 to 2) Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Warfarin (Coumadin) (Cont.)   Vitamin K Antidote for warfarin overdose 24 to 48 hours to be effective For acute bleeding, fresh frozen plasma is indicated. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Xa Inhibitor: Oral Anticoagulants Rivaroxaban (Xarelto) Apixaban (Eliquis) Do not require routine coagulation monitoring Administered q.d. or b.i.d Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Anticoagulant Antagonists Vitamin K1 (phytonadione) Antagonist of warfarin Used for warfarin overdose or uncontrollable bleeding Usually 1 to 10 mg of vitamin K1 is given at once Failure to control bleeding: Fresh whole blood, fresh-frozen plasma or platelets Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Nursing Process: Warfarin and Heparin Assessment Nursing diagnosis Planning Nursing interventions Patient teaching Cultural considerations Evaluation Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Antiplatelets Used to prevent thrombosis in the arteries by suppressing platelet aggregation Heparin and warfarin prevent thrombosis in the veins. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Antiplatelets (Cont.) Prophylactic use in Prevention of myocardial infarction or stroke for patients with familial history Prevention of a repeat myocardial infarction or stroke Prevention of a stroke for patients having transient ischemic attacks Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Aspirin Effective and inexpensive treatment for suppressing platelet aggregation Long-term, low-dose therapy Inhibits cyclooxygenase, an enzyme needed by platelets to synthesize thromboxane A2 (TxA2) Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Other Antiplatelet Drugs Dipyridamole (Persantine) Ticlopidine (Ticlid) Clopidogrel (Plavix) Anagrelide HCl (Agrylin) Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) Ticagrelor (Brilinta) Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Thrombolytics Purpose Function Thrombolytic drugs Dissolve clot Promotes conversion of plasminogen to plasmin Thrombolytic drugs Streptokinase (Streptase) Urokinase (Abbokinase) Alteplase tPA (Activase) Reteplase rPA (Retavase) Tenecteplase TNK-tPA (TNKase) Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Thrombolytics (Cont.) Myocardial infarction Thrombolic stroke Thrombus, or blood clot, disintegrates when a thrombolytic drug is administered within 4 hours. Thrombolic stroke Thrombolytic drug should be administered within 3 hours. Pulmonary embolism DVT Noncoronary arterial occlusion from an acute thromboembolism Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Nursing Process: Thrombolytics Assessment Nursing diagnoses Planning Nursing interventions Patient teaching Cultural considerations Evaluation Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Case Study A patient is recovering from surgery to replace her right hip. In the early postoperative phase, the nurse anticipates administration of which drug to prevent deep vein thrombosis? Dipyridamole (Persantine) Low-molecular-weight heparin Abciximab (ReoPro) Anagrelide HCl (Agrylin) Answer: B Rationale: Low-molecular-weight heparins are derivatives of standard heparin and were introduced to prevent venous thromboembolism. The other drugs are platelet inhibitors. Antiplatelets are used to prevent thrombosis in the arteries by suppressing platelet aggregation. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Case Study The patient develops a deep vein thrombosis. The nurse anticipates administration of which medication? Intravenous heparin Clopidogrel (Plavix) Vitamin K Protamine sulfate (Protamine) Answer: A Rationale: Intravenous heparin is indicated for rapid anticoagulant effect when a thrombosis occurs because of a deep vein thrombosis (DVT), pulmonary embolism (PE), or an evolving stroke. The effects of subcutaneous heparin take longer to occur. Clopidogrel (Plavix) is an antiplatelet drug that is mainly for prophylactic use in prevention of myocardial infarction or stroke. Vitamin K is the antidote for warfarin, and protamine is the antidote for heparin. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Case Study The patient is being discharged home on warfarin (Coumadin) therapy. Which information will the nurse include when teaching the patient? Results of activated partial thromboplastin time (aPTT) will determine if the medication is effective. International normalized ratio (INR) results should be between 2 to 3. A normal response to warfarin (Coumadin) is for your stools to look tarry. Increase the amount of green leafy vegetables in your diet. Answer: B Rationale: Today, international normalized ratio (INR) is the laboratory test most frequently used to report PT results; a value of 2 to 3 is considered acceptable. Partial thromboplastin time (PTT) and activated partial thromboplastin time (aPTT) are laboratory tests to detect deficiencies of certain clotting factors, and these tests are used to monitor heparin therapy. Tarry stools indicate GI bleeding. Green leafy vegetables contain vitamin K, which is the antidote for warfarin (Coumadin). Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #1 A patient is prescribed aspirin, 81 mg, and clopidogrel (Plavix). The nurse identifies the drug classification of clopidogrel as anticoagulant. thrombotic inhibitor. antiplatelet. thrombolytic. Answer: C Rationale: Clopidogrel is an antiplatelet drug. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #2 A patient arrived in the emergency department 2 hours after an acute ischemic stroke. The patient is given an intravenous (IV) injection of alteplase tPA (Activase). It is most important for the nurse to monitor what? (Select all that apply.) Bleeding Vital signs PT levels Allergic reactions Electrocardiogram Answer: A, B, D, E Rationale: The nurse should monitor the patient receiving thrombolytics for adverse effects, such as bleeding, allergic reactions, and cardiac dysrhythmias. An increased heart rate with a decreased BP usually indicates blood loss from bleeding. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #3 Which information will the nurse include when teaching a patient about warfarin (Coumadin) therapy? Increase the amount of green, leafy vegetables in your diet. Rinse your mouth instead of brushing your teeth. Follow up with laboratory tests such as PT or INR to regulate warfarin (Coumadin) dose. Use a new razor blade each time you shave. Answer: C Rationale: Laboratory tests such as PT or INR are performed to regulate warfarin (Coumadin) dose. The patient should avoid consuming large amounts of green, leafy vegetables; broccoli; legumes; soybean oil; coffee; tea; cola; excessive alcohol, and certain nutritional supplements such as coenzyme Q10. Patients are encouraged to perform oral hygiene and use a soft tooth brush to prevent gums from bleeding. Patients should be instructed to use an electric razor when shaving. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #4 A patient manifests symptoms of a thrombolic stroke. The emergency department nurse is aware that thrombolytics need to be administered in this situation within how many hours of the onset of symptoms? 1 hour 2 hours 3 hours 4 hours Answer: D Rationale: A thrombolytic drug should be administered within 3 hours of a thrombolic stroke. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #5 A patient is on heparin therapy secondary to deep vein thromboses. The nurse has which medication on hand as an antidote in case it is needed? Vitamin K Protamine sulfate Warfarin (Coumadin) Aminocaproic acid (Amicar) Answer: B Rationale: Vitamin K is the antidote for warfarin (Coumadin), not heparin, therapy; warfarin (Coumadin) is an anticoagulant, and aminocaproic acid (Amicar) is a plasminogen inactivator used to control excessive bleeding from hyperfibrinolysis. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #6 Four patients are considered as potential candidates for thrombolytic therapy. Which patient is most likely to receive thrombolytic therapy? The patient who recently used acetaminophen (Tylenol) The patient with a history of severe hypertension The patient who recently had spinal surgery The patient with a history of warfarin (Coumadin) use Answer: A Rationale: Acetaminophen (Tylenol) does not interfere with the coagulation system. Contraindications for use of thrombolytics include a recent CVA, active bleeding, severe hypertension, recent history of traumatic injury, especially head injury, and anticoagulant therapy. The nurse should report if the patient takes aspirin or NSAIDs. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #7 The nurse is caring for a patient who received alteplase tPA (Activase) for treatment of acute coronary syndrome. The patient starts to bleed. The nurse anticipates administration of which medication? Protamine sulfate (protamine) Vitamin K (phytonadione) Warfarin (Coumadin) Aminocaproic acid (Amicar) Answer: D Rationale: Aminocaproic acid (Amicar) is used to stop bleeding by inhibiting plasminogen activation, which inhibits thrombolysis. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.

Practice Question #8 A patient visits an outpatient clinic. The patient has been noncompliant with anticoagulation therapy and states, “I don’t like having to have blood work all of the time.” The nurse anticipates prescription of which medication? Abciximab (ReoPro) Tirofiban (Aggrastat) Eptifibatide (Integrilin) Rivaroxaban (Xarelto) Answer: D Rationale: Two oral anticoagulants form a new anticoagulant category called Xa inhibitors. Rivaroxaban (Xarelto) was FDA-approved in July 2011, and apixaban (Eliquis) was FDA-approved in December 2012. These drugs do not require routine coagulation monitoring and are given q.d. or b.i.d. The other medications are administered intravenously. Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.